Jack Khattar, Supernus CEO
Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout
Supernus is marking its expansion into the Parkinson’s disease arena, striking a deal to buy out Adamas Pharmaceuticals in a deal worth more than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
